PD21-10 DUTASTERIDE IN THE LONG-TERM MANAGEMENT OF STUTTERING PRIAPISM

INTRODUCTION AND OBJECTIVES:Dutasteride has a uniquely long half-life of 35 days which offers a theoretical advantage as a chronic therapy for management of stuttering priapism. The objective of this study is to review our 12 year experience with the 5-α reductase inhibitor dutasteride as a potential long term treatment option for stuttering priapism.METHODS:We retrospectively reviewed patients with stuttering priapism in our database from 2006-2018 that were treated with dutasteride. Men with concurrent use of medications other than dutasteride to treat stuttering priapism were excluded. Patients were started on a dose of 0.5 mg daily and tapered to a more infrequent dosing schedule, ranging from 0.5 mg every other day to once weekly. Outcomes analyzed were the frequency of stuttering priapism episodes before and after initiation of dutasteride therapy.RESULTS:Among 21 cases, 13 patients met our inclusion criteria (mean age 43 years). Median follow-up on daily dutasteride was 79 days and mean follow-up o...